Skip to main content
. 2017 Oct 26;8(58):97822–97834. doi: 10.18632/oncotarget.22085

Figure 2. Chemical synthesis and dose optimization of P2X7R inhibitors A438079 and AZ10606120.

Figure 2

(A) Synthesis of A438079. (B) Synthesis of AZ10606120. (C) Experimental design for MTD/dose optimization study in mice. (D) Body weights of mice treated with A438079 for six weeks. (E) Body weights of mice treated with AZ10606120 for six weeks. (F) Pancreas weights of mice treated with A438079 for six weeks. (G) Pancreas weights of mice treated with AZ10606120 for six weeks. X- axis: body weight or pancreas weight in grams; y-axis: doses of A438079 or AZ10606120 in ppm. No significant difference in body weights and pancreas weights were observed in the P2X7R inhibitors (A438079 and AZ10606120) treatment groups compared to untreated.